Ketamine Inhibits NF-kappa B Activation and TNF-α Production Induced by LPS in Vivo

JI Qing,YANG Jian-jun,SUN Jie,XU Jian-guo

DOI: https://doi.org/10.3969/j.issn.1008-8199.2005.04.014

2005-01-01

Abstract:Objective: To investigate the effect of ketamine on the endotoxin-induced NF-kappa B (NF-κB) activation and TNF-α production in vivo. Methods: The sepsis model was induced by a bolus injection of endotoxin (5 mg/kg) into the tail vein of adult male Wistar rats. Then all animals were immediately treated with different doses of ketamine (0.5, 5, 50 mg/kg) or normal saline (10 ml/kg) intraperitoneally(ip). After two hours, the intestines, livers, lungs and kidneys of each rat were dissected and kept for NF-κB and TNF-α detection. Results: Endotoxin enhanced NF-κB activity and TNF-α production in the intestine, liver, lung and kidney. Ketamine at a dose of more than 0.5 mg/kg suppressed endotoxin-induced NF-κB activation and TNF-α production in the intestine and kidney. However, the least dose of ketamine to inhibit NF-κB activation and TNF-α production in the lung was 5 mg/kg. Three different doses of ,etamine (0.5, 5, 50 mg/kg) could not inhibit NF-κB activation and TNF-α production in the liver, while ketamine at the dose of 50 mg/kg enhanced NF-κB activity and TNF-α production in the liver. Conclusion: These findings suggest that ketamine can suppress NF-κB and TNF-α production in vivo. Subanesthetic dose of ketamine has anti-inflammatory effect. However, ketamine at a large dose of more than 50 mg/kg may be harmful to the endotoxin-induced sepsis.